Systemic AAV-hGCDH Gene Therapy Alleviates Glutaric Acid Accumulation and Attenuates Chronic Brain Vacuolation in a Novel Mouse Model of Glutaric Aciduria Type I
International Journal of Molecular Sciences · 20.06.2026 · 27 (12) · 5569
DOI: 10.3390/ijms27125569 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.06.2026. Verfasst von Su Jin Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Inha University Hospital, Inha University College of Medicine, Incheon 22332, Republic of Korea. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Glutaryl-CoA Dehydrogenase, Amino Acid Metabolism, Inborn Errors. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Inha University.
Abstract (Originalsprache)
Glutaric aciduria type 1 (GA1) is a rare neurometabolic disorder caused by glutaryl-CoA dehydrogenase (GCDH) deficiency, leading to the accumulation of neurotoxic metabolites that can cause both acute encephalopathic crises and progressive, insidious brain injury. Current management primarily relies on a protein-restricted diet, which remains therapeutically insufficient and burdensome for patients, highlighting the need for disease-modifying therapies. In this study, we established a novel GA1 mouse model using CRISPR/Cas9 technology and evaluated the preclinical efficacy of systemic recombinant adeno-associated virus (rAAV)-mediated gene therapy. Under standard dietary conditions without high-lysine challenge, our GA1 model exhibited sustained cerebral and hepatic glutaric acid (GA) accumulation and distinct chronic vacuolation in the hippocampus and cerebellum, mirroring the insidious-onset GA1 phenotype. Five-week-old mice received a single intravenous injection of rAAV-hGCDH using either rAAV2/8 or rAAV2/9 serotypes. Systemic rAAV-mediated gene therapy significantly reduced GA accumulation and attenuated chronic neuropathological changes in this GA1 mouse model for both serotypes. Our findings support the hypothesis that peripheral metabolic correction may play an important role in preventing the chronic neuropathological changes associated with GCDH deficiency. However, further investigation using tissue-specific expression systems is required to definitively delineate the relative contributions of hepatic versus central GCDH restoration to the observed neuroprotection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Inha University Hospital, Inha University College of Medicine, Incheon 22332, Republic of Korea.
- Department of Biochemistry, College of Medicine, Ewha Womans University, Seoul 07804, Republic of Korea.
- School of Medicine, Sungkyunkwan University, Suwon 16419, Republic of Korea.
ORCID-Profile: Su Jin Kim, Eun Young Joo, Saeyoung Park, Sung-Chul Jung
Förderung
- Inha University
Zitieren
APA
Kim, S. J., Nam, Y. H., Joo, E. Y., Park, J., Park, S., Jung, S. C., & Jin, D. K. (2026). Systemic AAV-hGCDH Gene Therapy Alleviates Glutaric Acid Accumulation and Attenuates Chronic Brain Vacuolation in a Novel Mouse Model of Glutaric Aciduria Type I. International Journal of Molecular Sciences, 27(12), 5569. https://doi.org/10.3390/ijms27125569
Vancouver
Kim SJ, Nam YH, Joo EY, Park J, Park S, Jung SC, et al. Systemic AAV-hGCDH Gene Therapy Alleviates Glutaric Acid Accumulation and Attenuates Chronic Brain Vacuolation in a Novel Mouse Model of Glutaric Aciduria Type I. International Journal of Molecular Sciences. 2026;27(12):5569. doi:10.3390/ijms27125569
BibTeX
@article{Kim2026,
author = {Kim, Su Jin and Nam, Yu Hwa and Joo, Eun Young and Park, Jisun and Park, Saeyoung and Jung, Sung-Chul and Jin, Dong-Kyu},
title = {Systemic AAV-hGCDH Gene Therapy Alleviates Glutaric Acid Accumulation and Attenuates Chronic Brain Vacuolation in a Novel Mouse Model of Glutaric Aciduria Type I},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {12},
pages = {5569},
doi = {10.3390/ijms27125569}
}
EUVIMED